The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug ...

As clinical trials continue to evolve, next-generation mobile technologies and applications are at the forefront of ...

From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The current status of the Biosecure Act is that it was passed ​ by the US House of Representatives on Sep 9, with a vote of ...

Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...

In today's regulatory landscape, ensuring data integrity is crucial for compliance and process visibility. How can ...

Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm ...

Evaxion’s proprietary AI-Immunology platform has shown in clinical trials that it can select clinically relevant cancer ...

The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is ...